Torrent Pharmaceuticals Ltd

Torrent Pharmaceuticals Ltd share price declined by 2.78% to Rs 4482.0 after the company's net profit eased 5.65% to Rs 534.0 crore, while revenue from operations slightly gained 1.26% to Rs 4896.0 crore in Q3FY26 over Q2FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 26.82 lakh crore, gaining 3.59%. It has softened by 2.75% over last one week and dipped slightly by 2.21% in last one month while the market capitalization of Torrent Pharmaceuticals Ltd has eased by 1.71% and 9.63% in the same period respectively. Profit before tax (PBT) of Torrent Pharmaceuticals Ltd stood at Rs 737.0 crore in Q3 FY26, declining 6.83% year-on-year, and rising 0.55% quarter-on-quarter. EBITDA came in at Rs 1676 crore, expanding by 50.99% YoY and remaining flat sequentially. Total expenses saw a slight increase of 1.87% to Rs 3922.0 crore in Q3FY26 over Q3FY25. During the quarter, cost of materials consumed stood at Rs 588.0 crore, marginally falling by 3.45% YoY, while employee benefits expense was at Rs 895.0 crore, ticking higher by 0.22% YoY. For the TTM ended FY26, revenue from operations surged 21.53% to Rs 13753.0 crore, while net profit registered a growth of 11.88% to Rs 2138.0 crore, compared to previous TTM. EBITDA surged by 402100% to Rs 4653.0 crore, and PBT saw a minor gain of 7.44% to Rs 2872.0 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 3023.0 crore in FY26, as against Rs 2585.0 crore in FY25. Torrent Pharmaceuticals Ltd jumped 23.90% in last one year, significantly outperforming the benchmark BSE Sensex which has reduced by 13.52% during the same period.

Torrent Pharmaceuticals Ltd share price ticked higher by 1.82% to Rs 4610.15 after the company's net profit softened by 5.65% to Rs 534.0 crore, while revenue from operations improved marginally 1.26% to Rs 4896.0 crore in Q3FY26 over Q2FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 26.82 lakh crore, gaining 3.59%. It has eased by 2.75% over last one week and edged lower by 2.21% in last one month while the market capitalization of Torrent Pharmaceuticals Ltd has slipped by 1.71% and 9.63% in the same period respectively. Profit before tax (PBT) of Torrent Pharmaceuticals Ltd stood at Rs 737.0 crore in Q3 FY26, slipping 6.83% year-on-year, and easing 0.55% quarter-on-quarter. EBITDA came in at Rs 1676 crore, expanding by 50.99% YoY and remaining flat sequentially. Total expenses inched up 1.87% to Rs 3922.0 crore in Q3FY26 over Q3FY25. During the quarter, cost of materials consumed stood at Rs 588.0 crore, softening by 3.45% YoY, while employee benefits expense was at Rs 895.0 crore, ticking higher by 0.22% YoY. For the TTM ended FY26, revenue from operations surged 21.53% to Rs 13753.0 crore, while net profit expanded by 11.88% to Rs 2138.0 crore, compared to previous TTM. EBITDA witnessed a strong improvement of 402100% to Rs 4653.0 crore, and PBT saw a minor gain of 7.44% to Rs 2872.0 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 3023.0 crore in FY26, as against Rs 2585.0 crore in FY25. Torrent Pharmaceuticals Ltd rallied 27.45% in last one year, significantly outperforming the benchmark BSE Sensex which has declined by 13.37% during the same period.

Torrent Pharmaceuticals Ltd announced that India Ratings and Research Private Limited has affirmed the credit rating and revised the outlook from stable to positive of the company’s existing banking facilities, issuer rating, and Non-Convertible Debentures, assigning a rating of IND AA+/Positive; additionally, India Ratings and Research Private Limited has affirmed and assigned the credit rating for the existing and proposed Commercial Paper of the company respectively at IND A1+.

Torrent Pharmaceuticals Ltd. will hold a board meeting on Friday, October 23, 2026, to consider and approve the audited financial results on a standalone basis and unaudited financial results (with limited review) on a consolidated basis for the quarter and half year ended September 30, 2026.

Torrent Pharmaceuticals Ltd. informed the Bombay Stock Exchange and National Stock Exchange of India that the trading window for dealing in the company's securities by designated persons will be closed from October 1, 2026, and will reopen 48 hours after the submission of financial results for the quarter ended September 30, 2026, to the stock exchanges.

Torrent Pharmaceuticals Limited announced an amendment to a Share Subscription and Shareholders’ Agreement to increase its investment in Torrent Urja 27 Private Limited from Rs 79,193,400 to Rs 11,87,90,100, acquiring an additional stake to reach 26% in the captive hybrid (solar + wind) power project company incorporated in Gujarat on August 6, 2024. The increased investment will fund an expansion of the project capacity, and the transaction is being carried out at arm’s length, as Torrent Urja is an associate company and a step-down subsidiary of Torrent Pharmaceuticals’ holding company.

Torrent Pharmaceuticals Ltd fell for a fifth straight session today. The stock is quoting at Rs 4926.5, down 0.6% on the day as on 13:19 IST on the NSE. The benchmark NIFTY is down around 0.36% on the day, quoting at 24546.45. The Sensex is at 78526.31, down 0.54%.Torrent Pharmaceuticals Ltd has gained around 1.23% in last one month.Meanwhile, Nifty Pharma index of which Torrent Pharmaceuticals Ltd is a constituent, has increased around 4.18% in last one month and is currently quoting at 26564.8, down 0.27% on the day. The volume in the stock stood at 1.91 lakh shares today, compared to the daily average of 9.09 lakh shares in last one month. The benchmark August futures contract for the stock is quoting at Rs 4947.5, down 1.08% on the day. Torrent Pharmaceuticals Ltd jumped 37.87% in last one year as compared to a 0.75% rally in NIFTY and a 23.79% spurt in the Nifty Pharma index.The PE of the stock is 92.08 based on TTM earnings ending June 26.

Torrent Pharmaceuticals informed the Bombay Stock Exchange and National Stock Exchange that Ameera Shah has ceased to be an Independent Director of the company on August 1, 2026, after completing her term.

Torrent Pharmaceuticals informed the Bombay Stock Exchange and National Stock Exchange that Hasmukh Patel, Sushil Jaiswal, and Sunil Nadkarni have ceased to be part of the company's senior management, effective July 30, 2026, due to a change in reporting structure.

Net profit of Torrent Pharmaceuticals rose 3.28% to Rs 566.00 crore in the quarter ended June 2026 as against Rs 548.00 crore during the previous quarter ended June 2025. Sales rose 54.57% to Rs 4835.00 crore in the quarter ended June 2026 as against Rs 3128.00 crore during the previous quarter ended June 2025. ParticularsQuarter EndedJun. 2026Jun. 2025% Var. Sales4835.003128.00 55 OPM %34.4232.99 - PBDT1347.00939.00 43 PBT754.00738.00 2 NP566.00548.00 3 Powered by Capital Market - Live